10q10k10q10k.net

vs

Side-by-side financial comparison of PRECISION BIOSCIENCES INC (DTIL) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $34.2M, roughly 1.3× PRECISION BIOSCIENCES INC). PRECISION BIOSCIENCES INC runs the higher net margin — 58.9% vs -90.4%, a 149.3% gap on every dollar of revenue. On growth, PRECISION BIOSCIENCES INC posted the faster year-over-year revenue change (5261.1% vs 13.8%). PRECISION BIOSCIENCES INC produced more free cash flow last quarter ($-11.3M vs $-19.9M). Over the past eight quarters, PRECISION BIOSCIENCES INC's revenue compounded faster (39.5% CAGR vs 7.3%).

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

DTIL vs PACB — Head-to-Head

Bigger by revenue
PACB
PACB
1.3× larger
PACB
$44.6M
$34.2M
DTIL
Growing faster (revenue YoY)
DTIL
DTIL
+5247.3% gap
DTIL
5261.1%
13.8%
PACB
Higher net margin
DTIL
DTIL
149.3% more per $
DTIL
58.9%
-90.4%
PACB
More free cash flow
DTIL
DTIL
$8.7M more FCF
DTIL
$-11.3M
$-19.9M
PACB
Faster 2-yr revenue CAGR
DTIL
DTIL
Annualised
DTIL
39.5%
7.3%
PACB

Income Statement — Q4 2025 vs Q4 2025

Metric
DTIL
DTIL
PACB
PACB
Revenue
$34.2M
$44.6M
Net Profit
$20.1M
$-40.4M
Gross Margin
37.1%
Operating Margin
36.6%
-92.3%
Net Margin
58.9%
-90.4%
Revenue YoY
5261.1%
13.8%
Net Profit YoY
213.5%
-1802.7%
EPS (diluted)
$2.62
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.

Revenue
DTIL
DTIL
PACB
PACB
Q4 25
$34.2M
$44.6M
Q3 25
$13.0K
$38.4M
Q2 25
$18.0K
$39.8M
Q1 25
$29.0K
$37.2M
Q4 24
$638.0K
$39.2M
Q3 24
$576.0K
$40.0M
Q2 24
$49.9M
$36.0M
Q1 24
$17.6M
$38.8M
Net Profit
DTIL
DTIL
PACB
PACB
Q4 25
$20.1M
$-40.4M
Q3 25
$-21.8M
$-38.0M
Q2 25
$-23.5M
$-41.9M
Q1 25
$-20.6M
$-426.1M
Q4 24
$-17.7M
$2.4M
Q3 24
$-16.4M
$-60.7M
Q2 24
$32.7M
$-173.3M
Q1 24
$8.6M
$-78.2M
Gross Margin
DTIL
DTIL
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
DTIL
DTIL
PACB
PACB
Q4 25
36.6%
-92.3%
Q3 25
-158976.9%
-101.1%
Q2 25
-121538.9%
-112.8%
Q1 25
-76248.3%
-1154.5%
Q4 24
-3894.4%
-390.1%
Q3 24
-3693.6%
-160.3%
Q2 24
48.4%
-488.3%
Q1 24
-23.8%
-209.6%
Net Margin
DTIL
DTIL
PACB
PACB
Q4 25
58.9%
-90.4%
Q3 25
-167476.9%
-98.9%
Q2 25
-130666.7%
-105.4%
Q1 25
-70913.8%
-1146.8%
Q4 24
-2781.3%
6.0%
Q3 24
-2851.6%
-151.9%
Q2 24
65.6%
-481.3%
Q1 24
48.8%
-201.4%
EPS (diluted)
DTIL
DTIL
PACB
PACB
Q4 25
$2.62
$-0.11
Q3 25
$-1.84
$-0.13
Q2 25
$-2.13
$-0.14
Q1 25
$-2.21
$-1.44
Q4 24
$-3.08
$-0.44
Q3 24
$-2.25
$-0.22
Q2 24
$4.67
$-0.64
Q1 24
$1.70
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.

Metric
DTIL
DTIL
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$115.6M
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$92.2M
$5.3M
Total Assets
$154.4M
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.

Cash + ST Investments
DTIL
DTIL
PACB
PACB
Q4 25
$115.6M
$279.5M
Q3 25
$44.9M
$298.7M
Q2 25
$62.2M
$314.7M
Q1 25
$77.2M
$343.1M
Q4 24
$86.3M
$389.9M
Q3 24
$101.2M
$471.1M
Q2 24
$123.6M
$509.8M
Q1 24
$137.8M
$561.9M
Stockholders' Equity
DTIL
DTIL
PACB
PACB
Q4 25
$92.2M
$5.3M
Q3 25
$16.6M
$36.1M
Q2 25
$34.1M
$61.5M
Q1 25
$49.3M
$91.6M
Q4 24
$56.4M
$506.6M
Q3 24
$64.9M
$453.1M
Q2 24
$74.7M
$492.7M
Q1 24
$37.2M
$649.0M
Total Assets
DTIL
DTIL
PACB
PACB
Q4 25
$154.4M
$784.1M
Q3 25
$93.5M
$803.2M
Q2 25
$108.9M
$825.5M
Q1 25
$124.4M
$860.8M
Q4 24
$136.4M
$1.3B
Q3 24
$153.3M
$1.5B
Q2 24
$165.8M
$1.5B
Q1 24
$184.7M
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.

Metric
DTIL
DTIL
PACB
PACB
Operating Cash FlowLast quarter
$-11.3M
$-19.1M
Free Cash FlowOCF − Capex
$-11.3M
$-19.9M
FCF MarginFCF / Revenue
-32.9%
-44.6%
Capex IntensityCapex / Revenue; lower = less reinvestment burden
0.1%
1.9%
Cash ConversionOCF / Net Profit; >1× = earnings back up with cash
-0.56×
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.

Operating Cash Flow
DTIL
DTIL
PACB
PACB
Q4 25
$-11.3M
$-19.1M
Q3 25
$-15.3M
$-18.7M
Q2 25
$-20.3M
$-29.4M
Q1 25
$-19.1M
$-44.1M
Q4 24
$-18.7M
$-30.6M
Q3 24
$-5.9M
$-45.5M
Q2 24
$-14.9M
$-54.3M
Q1 24
$-19.0M
$-75.7M
Free Cash Flow
DTIL
DTIL
PACB
PACB
Q4 25
$-11.3M
$-19.9M
Q3 25
$-18.8M
Q2 25
$-20.3M
$-29.9M
Q1 25
$-19.1M
$-45.4M
Q4 24
$-18.8M
$-32.3M
Q3 24
$-6.0M
$-46.3M
Q2 24
$-14.9M
$-55.7M
Q1 24
$-19.1M
$-79.6M
FCF Margin
DTIL
DTIL
PACB
PACB
Q4 25
-32.9%
-44.6%
Q3 25
-48.9%
Q2 25
-112627.8%
-75.3%
Q1 25
-65917.2%
-122.3%
Q4 24
-2943.6%
-82.3%
Q3 24
-1033.2%
-115.7%
Q2 24
-29.9%
-154.8%
Q1 24
-108.4%
-205.0%
Capex Intensity
DTIL
DTIL
PACB
PACB
Q4 25
0.1%
1.9%
Q3 25
0.0%
0.2%
Q2 25
11.1%
1.4%
Q1 25
220.7%
3.7%
Q4 24
15.2%
4.1%
Q3 24
6.8%
2.0%
Q2 24
0.1%
4.1%
Q1 24
0.5%
10.0%
Cash Conversion
DTIL
DTIL
PACB
PACB
Q4 25
-0.56×
Q3 25
Q2 25
Q1 25
Q4 24
-12.93×
Q3 24
Q2 24
-0.45×
Q1 24
-2.21×

Financial Flow Comparison

Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.

Revenue Breakdown by Segment

DTIL
DTIL

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons